FDA approves 'artificial pancreas' algorithm for continuous glucose monitor | Regulatory news for the week of November 10, 2014

Here's a look at some of the top regulatory stories for medical device companies this week: Diabetes: FDA OKs new 'artificial pancreas' software for DexCom glucose meter; FDA: Edap's Ablatherm prostate cancer device 'not approvable'; Cardiovascular Systems wins CE Mark for Stealth 360 peripheral artery device

Diabetes: FDA OKs new 'artificial pancreas' software for DexCom glucose meter

November 6, 2014 by Brad Perriello

Cardiovascular Systems Inc., DexCom Inc., EDAP TMS SA, Food & Drug Administration (FDA)

News Well, Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1GLHNvy